Abstract:Background Portal vein system thrombosis (PVST) is a frequent and possibly fatal concurrent disorder following splenectomy. The optimal anticoagulant to prevent PVST following splenectomy remains unclear. Objectives The purpose of this study was to compare the safety and efficacy of apixaban versus aspirin in preventing PVST after laparoscopic splenectomy (LS) for cirrhotic hypersplenism. Methods In this single-center randomized controlled trial, 80 patients with liver cirrhosis who received LS were randomly allocated to two treatment arms that were treated with apixaban or aspirin for 6 months. The primary effectiveness outcome was PVST formation after LS. Results We excluded four patients who withdrew from the study. The dynamic incidence of PVST, main and intrahepatic branches of PVST, and splenic vein thrombosis in the 6 postoperative months were all significantly lower in the apixaban treatment arm compared to the aspirin treatment arm (all P <0.001). Significantly lower incidences of PVST, main and intrahepatic branches of PVST, and splenic vein thrombosis in apixaban treatment arm started from postoperative day 7, month 1, and day 7 compared to the aspirin treatment arm respectively (all P <0.05). Multiple logistic regression analysis revealed that apixaban was an independent protective factor for PVST at postoperative month 3, as compared with aspirin (relative risk, 0.057; 95% confidence interval, 0.013–0.248; P <0.001). Conclusion Compared with aspirin, apixaban could earlier and more effectively prevent PVST following LS for cirrhotic hypersplenism. Apixaban can be chosen as a priority treatment option versus aspirin, contributing to a lower risk of PVST. The study protocol was approved by the Ethics Committee of the Clinical Medical College of Yangzhou University (No. 2020ky178). The data generated in this study are not publicly available due to the information that could compromise patient privacy, but are available upon reasonable request from the corresponding author. We obtained written informed consent from all patients enrolled in the study. Z.S. and K.X. evaluated the data and composed the initial draft of the manuscript. Z.S. and T.G. collected the data. C.Z. and B.Z. analyzed and reviewed the data. S.J. verified the data. D.B. and G.J. conceived and edited the manuscript. The manuscript was thoroughly revised by all the authors, and each of them reviewed and endorsed the ultimate edition; each author had full access to the entire set of study data. All the authors took the responsibility for making the decision to submit the manuscript for publication. * These authors contributed equally to this study. Received: 11 September 2024 Accepted: 23 November 2024 Article published online: 13 December 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Comparison of Apixaban and Aspirin in Preventing Portal Vein Thrombosis after Laparoscopic Splenectomy for Cirrhotic Hypersplenism

[Laparoscopic Splenectomy and Pericardial Devascularization for Treatment of Portal Hypertension Due to Liver Cirrhosis].

Preventive use of low molecular weight heparin in portal vein system thrombosis after splenectomy without portal hypertension

Laparoscopic splenectomy plus pericardial devascularization for the treatment of portal hypertension in cirrhotic patients

Preoperative splenic artery embolism followed by splenectomy is safe and effective in patients with sinistral portal hypertension

Comparison of two laparoscopic splenectomy plus pericardial devascularization techniques for management of portal hypertension and hypersplenism

Laparoscopic Splenectomy without Using Endo-GIA Combined with Pericardial Devascularization

Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis

Early Prophylactic Anticoagulation for Portal Vein System Thrombosis after Splenectomy: A Systematic Review and Meta-Analysis.

Era of Liver Transplantation: Combined Anatomic Splenectomy and Anticoagulant Therapy in Prevention of Portal Vein Thrombosis after Splenectomy.

Early Prophylactic Anticoagulation via Transjugular Intrahepatic Route for Portal Vein Thrombosis after Splenectomy in Cirrhotic Portal Hypertension

Effect of Low-Dose Aspirin Administration on Long-Term Survival of Cirrhotic Patients after Splenectomy: A Retrospective Single-Center Study

Postoperative Anticoagulants in Preventing Portal Vein Thrombosis in Patients Undergoing Splenectomy Because of Liver Cirrhosis: A Meta-Analysis

Rivaroxaban Versus Low-Molecular Weight Heparin Plus Warfarin Prevents Portal Vein System Thrombosis after Splenectomy and Pericardial Devascularization: A Randomized Clinical Trial.

What intervention regimen is most effective prevention for Portal venous system thrombosis after splenectomy in cirrhotics patients with Portal hypertension? Systematic review and network meta-analysis

Early use of low-molecular heparin to prevent portal thrombosis after splenectomy and pericardial devasculariza-tion in patients with portal hypertension

The decreased risk of hepatocellular carcinoma in hepatitis B virus-related cirrhotic portal hypertension patients after laparoscopic splenectomy and azygoportal disconnection

The Incidence and Risk Factors of Portal Vein System Thrombosis after Splenectomy and Pericardial Devascularization.

Laparoscopic splenectomy with or without devascularization of the stomach for liver cirrhosis and portal hypertension: a systematic review.

Comparison of prevention and treatment of portal vein thrombosis between proximal splenic vein ligation followed by postoperative transcatheter anticoagulant therapy and systemic anticoagulant therapy in patients with cirrhotic portal hypertension